Plancorp LLC Has $2.45 Million Stock Position in Abbott Laboratories (NYSE:ABT)

Plancorp LLC lifted its position in Abbott Laboratories (NYSE:ABT - Free Report) by 12.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 21,624 shares of the healthcare product maker's stock after purchasing an additional 2,432 shares during the quarter. Plancorp LLC's holdings in Abbott Laboratories were worth $2,446,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Welch Group LLC boosted its position in shares of Abbott Laboratories by 5.3% during the 4th quarter. Welch Group LLC now owns 68,653 shares of the healthcare product maker's stock valued at $7,744,000 after acquiring an additional 3,479 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich boosted its holdings in Abbott Laboratories by 5.5% during the fourth quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,095,443 shares of the healthcare product maker's stock valued at $133,691,000 after purchasing an additional 57,499 shares in the last quarter. Bath Savings Trust Co grew its stake in shares of Abbott Laboratories by 3.7% in the 4th quarter. Bath Savings Trust Co now owns 166,132 shares of the healthcare product maker's stock valued at $18,791,000 after purchasing an additional 5,881 shares during the period. Bank Pictet & Cie Europe AG lifted its position in shares of Abbott Laboratories by 1.9% during the 4th quarter. Bank Pictet & Cie Europe AG now owns 152,719 shares of the healthcare product maker's stock worth $17,274,000 after buying an additional 2,774 shares during the period. Finally, Pensionfund Sabic acquired a new stake in Abbott Laboratories in the 4th quarter valued at $2,828,000. 75.18% of the stock is owned by institutional investors.

Remove Ads

Insiders Place Their Bets

In other Abbott Laboratories news, EVP Lisa D. Earnhardt sold 91,167 shares of the business's stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $133.82, for a total value of $12,199,967.94. Following the sale, the executive vice president now owns 71,928 shares in the company, valued at approximately $9,625,404.96. The trade was a 55.90 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Daniel Gesua Sive Salvadori sold 23,771 shares of the firm's stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $128.50, for a total transaction of $3,054,573.50. Following the transaction, the executive vice president now directly owns 125,697 shares of the company's stock, valued at $16,152,064.50. This represents a 15.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 116,449 shares of company stock worth $15,463,316. Company insiders own 0.46% of the company's stock.

Abbott Laboratories Trading Up 0.7 %

Shares of ABT stock traded up $0.86 on Wednesday, reaching $126.46. The company had a trading volume of 6,053,463 shares, compared to its average volume of 5,471,811. The stock has a market cap of $219.31 billion, a PE ratio of 16.53, a PEG ratio of 2.52 and a beta of 0.70. The company has a 50-day moving average of $129.04 and a 200-day moving average of $120.12. The company has a current ratio of 1.60, a quick ratio of 1.14 and a debt-to-equity ratio of 0.32. Abbott Laboratories has a 12 month low of $99.71 and a 12 month high of $141.23.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its quarterly earnings results on Wednesday, January 22nd. The healthcare product maker reported $1.34 earnings per share for the quarter, hitting analysts' consensus estimates of $1.34. The company had revenue of $10.97 billion for the quarter, compared to analysts' expectations of $11.03 billion. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. The business's quarterly revenue was up 7.2% compared to the same quarter last year. During the same period last year, the firm posted $1.19 earnings per share. On average, equities analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, May 15th. Investors of record on Tuesday, April 15th will be paid a dividend of $0.59 per share. The ex-dividend date of this dividend is Tuesday, April 15th. This represents a $2.36 dividend on an annualized basis and a yield of 1.87%. Abbott Laboratories's payout ratio is 30.85%.

Analyst Ratings Changes

ABT has been the subject of a number of analyst reports. The Goldman Sachs Group lifted their price objective on Abbott Laboratories from $138.00 to $154.00 and gave the company a "buy" rating in a report on Tuesday, March 4th. Argus raised shares of Abbott Laboratories to a "strong-buy" rating in a research note on Tuesday, January 28th. Wells Fargo & Company lifted their target price on shares of Abbott Laboratories from $133.00 to $136.00 and gave the company an "overweight" rating in a research note on Thursday, January 23rd. Stifel Nicolaus raised their price target on Abbott Laboratories from $130.00 to $135.00 and gave the company a "buy" rating in a report on Thursday, January 23rd. Finally, Evercore ISI boosted their price objective on Abbott Laboratories to $136.00 and gave the stock a "buy" rating in a research note on Thursday, January 2nd. Four investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $137.94.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.